Gavi, the Vaccine Alliance is a public-private global health partnership, created in 2000 to bring together public and private sectors with the shared goal of creating equal access to new and underused vaccines for children living in the world’s poorest countries. Partners include developing country and donor governments, WHO, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society organisations, the Bill & Melinda Gates Foundation and other private philanthropists. WHO estimates that, in Gavi’s first decade, Gavi support has contributed to the immunisation of an additional 440 million children.
The Alliance is supported by a small Secretariat based in Geneva and Washington, DC.
MEMBERS OF THE GAVI ALLIANCE
The Bill & Melinda Gates Foundation
Civil Society Organisations
Developing Country Governments
Donor Country Governments
Research And Technical Health Institutes
Unaffiliated Board Members
The Vaccine Industry from the developing countries and industrialised countries
The World Bank Group
SUPPORT COUNTRIES CAN APPLY FOR
new and underused vaccines support;
health system strengthening support;
support to civil society involvement in immunisation planning and delivery;
immunisation services support (performance-based cash support) and
injection safety support.
COUNTRIES ELIGIBLE FOR GAVI SUPPORT
Gavi aims to focus on the world’s poorest countries. Eligibility is therefore determined by national income with all countries with a Gross National Income (GNI) per capita below or equal to US$1,570 (according to Wold Bank data for the latest available year) qualifying for support.
There are currently 53 Gavi-eligible countries. However, not all of these countries qualify for every type of support because Gavi sets conditions for each type of support.
Support is provided in response to country proposals, which are reviewed by an independent group of experts – mostly health officials from developing countries.
Gavi support is available to the 73 poorest countries in the world. By the end of 2013, 22 countries were projected to graduate from Gavi’s support by 2020.
Gavi’s Board has approved a revised five-year strategy to continue to build sustainable programmes and deliver on its mission to save children’s lives and protect people’s health by increasing equitable use of vaccines in lower income countries.
The revised five-year strategy (2016-2020), approved by the Gavi Board on 19 June 2014, builds on the current strategy and draws lessons from the previous 15 years. The strategy is designed to adapt to the changing environment in which the Vaccine Alliance and the countries it is supporting will operate
The 2016-20 strategy has four goals, each supporting Gavi’s overall mission: “to save children’s lives and protect people’s health by increasing equitable use of vaccines in lower income countries.”
Accelerate equitable uptake and coverage of vaccines.
Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems.
Improve sustainability of national immunisation programmes.
Shape markets for vaccines and other immunisation products.
The strategic framework includes eight principles, intended to define the Vaccine Alliance’s characteristics, its business model and its aspirations: country-led, community-owned, globally engaged, catalytic and sustainable, integrated, innovative, collaborative and accountable.
Vaccines have a long-term positive impact beyond health outcomes. Expanded immunisation in Gavi-supported countries from 2016 to 2020 could deliver more than 100 million illness cases averted. This will reduce the burden of care on parents, improving their productivity and freeing them from crippling medical costs. And by protecting children from infectious diseases, vaccines will also help raise IQ levels.
Renewed investment from donors, together with co-financing from recipient countries and support from vaccine manufacturers, will help immunise an additional 300 million children from 2016-2020. This will result in 5-6 million lives saved and economic benefits of US$ 80-100 billion
GAVI’S ACHIEVEMENTS SO FAR
Since its launch in 2000, Gavi has helped developing countries to prevent 6 million future deaths from hepatitis B, Haemophilus influenzae type b (Hib), measles, meningitis A, pneumococcal disease, rotavirus diarrhoea and yellow fever.
Immunisation coverage for three doses of the diphtheria-tetanus-pertussis vaccine (DTP3) reached 76% in 2013 in the 73 countries supported by the Alliance.
Through the Advance Market Commitment, pneumococcal vaccines are available to GAVI-eligible countries at no more than US$ 3.50 per dose, a more than 90% reduction compared with the public price in the United States. In 2013, Gavi secured a lowest price offer for pneumococcal vaccines of US$ 3.30 per dose from 2014 onwards.
Gavi works with manufacturers to bring down HPV prices. In 2013, a new price of US$ 4.50 per dose was agreed, a two-thirds reduction on the current lowest public price.
Through a catalytic programme of support, GAVI has helped set new standards for injection safety.
Where is GAVI, the Vaccine Alliance